VEGFA and non-small cell lung carcinoma: Bevacizumab, which targets VEGF, was approved by the Food and Drug Administration in 2006 for treating advanced NSCLC,89 and several VEGFR tyrosine kinase inhibitors have been approved in combination with chemotherapy for metastatic NSCLC.90